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Abstract
Background: Contemporary information relating to the prevalence of Toxoplasma gondii in humans is lacking for
the UK population, with even less information available about the human prevalence of the parasite in Scotland. To
address this, two different study groups were used to determine the prevalence and genotypes of Toxoplasma
gondii in the Scottish population.
Methods: The first study group included serum samples from blood donors (n = 3273) over a four-year period
(2006–2009) and the second study group comprised of DNA samples extracted from human brains (n = 151) over a
five-year period (2008–2012). A T. gondii IgG ELISA was performed to determine seroprevalence and available sera
from individuals who had seroconverted were tested by TgERP ELISA (sporozoite specific antigen). Human brain
DNA was tested for T. gondii by ITS1 PCR and positives genotyped at the SAG3 and GRA6 loci by PCR-RFLP analysis.
Results: Seroprevalence to T. gondii from blood donors was found to be 13.2 % (95 % CI: 11.5–15.1 %). Evidence of
seroconversion (n = 2) as well as reversion to sero-negative status (n = 6) was evident from blood donors who had
donated within all four collection periods (n = 184). The TgERP ELISA (indicating oocyst infection) was positive for
one individual. The molecular detection of T. gondii DNA from human brains indicated a prevalence of 17.9 %
(95 % CI: 12.1–24.9 %), with genotyping identifying alleles for types I and III. An increase in age was associated with
an increase in detection of the parasite within both study groups.
Conclusions: Our research provides current figures for the prevalence of T. gondii in Scotland and also shows
evidence of seroreversion within the cohort of blood donors. In both study groups there was a correlation between
increasing age and an increase in T. gondii prevalence, indicating that acquired infection plays an important role
within the Scottish population.
Keywords: Toxoplasma gondii, Human brains, Blood donors, Serology, Longitudinal study, Seroprevalence,
Seroreversion, Genotyping
Background
One third of the human population are predicted to be
infected with Toxoplasma gondii [1]. However, current
prevalence figures for the UK are limited and even less
information is available specifically for Scotland, with a
recent document published by the Advisory Committee
on the Microbiological Safety of Food stating that there
is no information about current seroprevalence rates in
the UK [2]. Infection with T. gondii is generally asymp-
tomatic, however those who are immunocompromised,
or women who acquire the infection for the first time
during pregnancy, are particularly at risk of severe dis-
ease [3]. Women who test seronegative for T. gondii at
the beginning of pregnancy are at risk of becoming in-
fected with the parasite during pregnancy which may re-
sult in miscarriage and future complications with the
unborn child. Links have been made between T. gondii
infection and various psychological problems, such as
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schizophrenia, suicide and increased risk taking behav-
iour [4–6]. Currently there are no firm reports in the
literature linking T. gondii infection to these psychological
conditions in humans.
The majority of seroprevalence studies have focused
on pregnant women [7–9], and this specific group are
not representative of the population as a whole. UK
prevalence data which was published for the general
population was completed up to two decades ago and
studies reported a wide range of seroprevalence of be-
tween 7.7 and 40 % [2, 10]. Due to different farming
practices (i.e. UK consumers are now beginning to
favour meat from animals which have been raised from
farms incorporating more animal friendly practices, such
as outdoor reared pigs), food-producing animals may
have greater exposure to environmental oocysts. Conse-
quently, this increases their risk of becoming infected
and therefore may increase the opportunity for transmis-
sion to humans from consumption of undercooked meat
containing the parasite [11].
Until recently, determining whether a seropositive in-
dividual had become infected via oocysts or tissue cysts
was not possible. However, recent research has shown
that an ELISA incorporating the sporozoite specific anti-
gen (T. gondii embryogenesis-related protein [TgERP])
can assist in identifying individuals who have been in-
fected by ingestion of oocysts [12].
With the objective of obtaining a more up-to-date esti-
mate for the prevalence and genotypes of human T. gon-
dii infection in Scotland, the research within the current
study examined two different groups of individuals: (i)
serum samples from two cohorts of blood donors within
Scotland over a four-year period (2006–2009); and (ii)
human brain tissues from individuals who died suddenly
within Scotland over a five-year period (2008–2012).
In addition to providing contemporary figures for the
prevalence of T. gondii in the Scottish population, the
samples may provide links between T. gondii infection
and age, gender, or cause of death. The research will also
identify whether seroconversion or reversion of T. gondii
IgG has occurred, and whether recent infections were
due to the tissue cysts or oocysts. Finally, there is limited
information on strains that infect immunocompromised
individuals (such as HIV and organ transplant patients)
[13], and even less data regarding which strains infect
the general population. Non archetypal and genetically
distinct strains of the parasite (which have been identi-
fied in Brazil and South America), are known to be more
virulent to humans (and animals) than the archetypal
strains [14]. Therefore, molecular detection of the para-
site from human brains will allow strain genotyping,
providing information which will be more representative
of the general population and will provide an indication
whether any atypical strains are present.
Methods
Human reference sera
Reference/control sera were obtained from the Scottish
Toxoplasma Reference Laboratory (Scottish Toxoplasma
Reference Laboratory, Inverness, UK), who routinely test
human samples for the presence of T. gondii IgG. The
control sera supplied had previously been tested by
Sabin-Feldman dye test and calibrated as international
units per milliliter (IU/ml) as defined by the World
Health Organisation. Control sera enabled the standard-
isation of an in-house T. gondii IgG ELISA and also acted
as reference sera for testing all human sera. Controls were
comprised of 125 IU/ml (strong positive), 30 IU/ml (posi-
tive), 8 IU/ml (borderline), < 2 IU/ml (negative).
Human test sera
Serum samples were obtained from the Scottish Parasite
Diagnostic Laboratory. This laboratory provided a total
of 3273 serum samples from 1403 blood donors taken
over four different collection periods from April 2006
until February 2009 (2006–2009) from two different
cohorts (n = 1102 and n = 301). Each individual was
anonymised using a specific ID number which enabled
tracking of individuals throughout each collection
period. Basic donor information regarding age and gen-
der was made available from a database which had been
generated by Health Protection Scotland.
Human anti T. gondii IgG ELISA
In order to test the human serum samples, a human
anti-T. gondii IgG ELISA was optimised during this
study. Control sera, individual test sera and serum blank
controls were tested in duplicate. This methodology was
adapted from [15]. Briefly, each microwell of a Greiner
Bio-One 96 well medium binding plates was coated with
100 μl of solubilized T. gondii RH antigen at a concen-
tration of 6 μg/ml in carbonate buffer pH 9.6 and incu-
bated at 4 °C overnight. Following incubation, the plate
was washed 3 times with 300 μl PBS (pH7.2) containing
0.05 % Tween 20 (PBST). Control sera and test sera
were diluted 1/100 in PBST and 100 μl of the dilution
added to the appropriate microwell, in duplicate. Plates
were incubated at room temperature (22–25 °C) for one
hour. Plates were washed three times with PBST as
previously, followed by addition of 100 μl conjugate
(anti-human IgG alkaline phosphatase, Sigma Aldrich,
Dorset, UK) to each microwell, diluted 1/1000 in PBST.
Plates were incubated for one hour at room temperature.
Following incubation, each well was washed 3 times in
PBST as previously described and 100 μl of one-step PNPP
(Thermo Scientific Pierce, Cramlington, Northumberland,
UK) was added to each well. The plate was incubated in
the dark at room temperature for 30 min. Optical density
(OD) was measured at 405 nm using a Dynex-MRXII
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microplate reader (Dynex Technologies Limited, Wor-
thing, West Sussex, UK) installed with Revelation software.
OD values were corrected for blank measurements and
plate to plate variation as described below.
Corrected ELISA OD values and plate to plate variation
To analyse variation between each plate when testing
serum samples using the human IgG ELISA, the meth-
odology as described in [15] was used. Briefly, positive
and negative control samples (as previously described)
and serum blank controls (both tested in duplicate),
were added to each plate. Once all OD readings were
measured, the average OD readings for blank controls
on each plate were subtracted from the OD values of the
sera on that specific plate. These blank corrected OD
values for the serum control samples (n = 8 - duplicates
of each positive and negative control sample) were plot-
ted against their appropriate average blank corrected
OD value over all the plates tested (a regression line).
Using the appropriate regression line the standardised
blank corrected OD values for the test sera on that spe-
cific plate were calculated (their ODc value). Plates were
excluded if: (i) any of the duplicates for more than one
of the control samples had a coefficient of variation (CV
= standard deviation of replicates/mean of replicates)
above 20 %, or (ii) if the R2 value was less than 0.95. In
addition, individual sera were excluded from analysis if
the CV value was above 20 %, except if both duplicates
of the same sample had an OD value below 0.1, as in
that case, any CV value was accepted. Finally, as some of
the ODc values were negative a blank value of 0.05 was
added for all sera and all ODc values were 10log10-trans-
formed (log(ODc)-values).
Determining seroprevalence in Scottish blood donors
using a binomial mixture model
In a seropositive or seronegative population, the distri-
bution of log(ODc)-values usually follow a normal distri-
bution [16]. This allows for analysis of the size of the
seropositive and seronegative strata of the population,
both of which are presumed to be log-normally distrib-
uted but with a different standard deviation and mean.
A binomial mixture model takes these factors into ac-
count, and estimates two standard deviations, two means
and the mixing parameter. The prevalence estimated is
determined by the mixing parameter. This method does
not require a cut-off to estimate population prevalence.
However, when the status of individual samples is re-
quired, the mixture model can be used to determine
cut-off values, as shown in the following section. The bi-
nomial mixture model was performed in Mathematica
(v7.0, Wolfram Research, Illinois, USA), as described in
[15]. The binomial mixture model was used to deter-
mine a cut-off value using a receiver operating
characteristic (ROC) curve. This incorporated the two
distributions from a binomial mixture model where the
sum of sensitivity and specificity was maximized [15].
Identification of sporozoite specific antibodies in serum
samples from individuals that seroconverted
Once the cut of value had been determined, 50 μl of
serum from individuals who had been identified as sero-
negative at one collection period, but who later became
seropositive within a subsequent collection period (showing
seroconversion within the previous 6–8 months), were
tested for the identification of antibodies to the sporozoite
specific antigen T. gondii embryogenesis-related protein
(TgERP). This protein elicits an antibody response in
humans (and also mice and pigs), who have previously
been exposed to sporulated oocysts, therefore identifying
individuals that have been infected with this stage of the
parasite. The methodology for the ELISA is described in
[12], briefly, 96 well plates were coated with 2 μg/ml TgERP
in 0.1 M carbonate buffer, pH 9.6 the ELISA and interpret-
ation of results were completed as described in [17].
Human brain samples
Tissue samples for molecular detection of the parasite
from human brains were collected (n = 151) over a five-
year period (2008–2012) from the Medical Research
Council Sudden Death Brain and Tissue Bank (MRC Sud-
den Death Brain and Tissue Bank, Edinburgh, Scotland -
Research Ethics Committee approval, LREC 2003/8/37)
over a five-year collection period (2008–2012). The Brain
Bank works within the legal framework of the Human Tis-
sue (Scotland) Act 2006 and each individual had died sud-
denly (no known underlying illness or disease). A total of
approximately 3 g of frozen tissue was collected from
three specific regions of hind brain (pons, cerebellum and
medulla) for detection of parasite DNA. To access these
samples a research application was submitted and ap-
proved by the South East Scotland Research Ethics Com-
mittee (NHS Lothian, Edinburgh, Scotland), reference
number; REC number 11/AL/0113, IRAS project number
69852. Basic patient information was also provided with
these samples to determine whether there were any spe-
cific relationships between cause of death and detection of
T. gondii, and also to identify any trends between age and
gender and parasite prevalence.
DNA extraction, detection and genotyping of T. gondii
from human brains
DNA was extracted from human brains using 3 g of
pooled tissue (1 g of each; pons, cerebellum and me-
dulla). Each pool was transferred into a gentleMACS M
tube (Miltenyi Biotec, Woking, Surrey, UK) containing
6mls of Nuclei Lysis Solution (Promega) and samples
homogenised using a GentleMacs tissue dissociator
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(Miltenyi Biotec). All homogenate was transferred into a
15 ml centrifuge tube and incubated overnight at 55 °C.
Following incubation, samples were cooled to room
temperature and 1.5 ml Protein Precipitation Solution
(Promega) was added and mixed by inversion several
times, then incubated on ice for five minutes. Samples
were centrifuged at 1200 g for 30 min and supernatant
transferred into a 15 ml centrifuge tube containing
7.5 ml isopropanol. After gentle mixing by inversion,
precipitated DNA was centrifuged for ten minutes at
1000 g and the pellet washed with 2 ml 70 % ethanol,
supernatant removed and pellet briefly air dried and re-
suspended in 700 μl distilled H2O. The DNA was stored
at 4 °C for immediate use or at -20 °C for longer term
storage.
Following the extraction of DNA from human brain
tissue, samples were used to detect the presence of T.
gondii DNA using a diagnostic nested ITS1 PCR (based
on the multicopy ITS1 region [18]) and genotyping was
completed on positive samples using two molecular
markers (based on the single copy SAG3 and GRA6
markers [19]). The methodology for both these tech-
niques is fully described in [20].
Results
Seroprevalence and determination of cut-off value using
a binomial mixture model and ROC curve analysis
All results from collection period 1 (n = 947 individuals)
were used to formulate a binomial mixture model (Fig. 1).
Collection period 1 was used to produce the model, as this
group contained the greatest number of individuals. Using
the statistical methodology described in the methods, the
binomial mixture model was fitted and distributions were
plotted.
The binomial mixture model describes the overall T.
gondii seroprevalence for the first donation period,
which is estimated at 11.0 %. Performing ROC curve
analysis in the data derived from the binomial mixture
model results in a cut-off value of logODc = -0.48, with
an estimated sensitivity of 99.0 % and specificity of
99.4 %. This cut-off value was used for further analysis
of all donations; determining seropositivity with age,
gender and location, across all donation periods. Using
this newly defined cut-off value, T. gondii seroprevalence
for the first donation period was estimated at 11.9 %.
Overall seroprevalence determined by cut-off value and
seroprevalence within each collection period
Using the cut-off value (logODc = -0.48), the overall
prevalence of T. gondii during the four-year collection
period (2006–2009) from participating blood donors was
estimated at 13.2 % (95 % CI: 11.5–15.1 %) (185/1403)
(Table 1). This figure took into account repeat donations
from the same individual, including each individual only
once throughout all collection periods, with a donor
considered positive when a positive result was obtained
for any submitted sample. This cut-off value was also
used to determine seroprevalence within each collection
period (Table 1) and seropositivity was similar in all col-
lection periods. Again, repeat donations were common
Fig. 1 Frequency distribution of logODc values generated from Scottish blood donors (n = 947, period 1) using the human anti-IgG T. gondii
ELISA. Bars represent individual blood donors, and the curved line shows the normal distributions fitted by binomial mixture analysis. The black
dashed line indicates the cut-off value (log ODc -0.48) used for subsequent analysis
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from blood donors throughout an individual collection
period and repeat donors were counted as positive when
a positive result was obtained for any submitted sample.
Seroprevalence of T. gondii from blood donors in relation
to age and gender determined by cut-off value
Over the four-year period, donations were reasonably
consistent throughout each age group, 30–42 age group =
28.9 % (406/1403), 17–29 age group = 28.4 %, (398/1403),
43–55 age group = 28.0 % (393/1403), 56–69 age group =
14.7 % (206/1403).
There was a clear positive relationship between in-
creasing age and an increasing percentage of T. gondii
seropositivity. The 56–69 age group had the highest
prevalence at 27.2 % (56/206) (95 % CI: 19.5–31.7 %),
whilst the lowest prevalence of 6.3 % (25/398) (95 % CI:
4.1–9.1 %) was observed in the 17–29 age group (Fig. 2).
When gender is also taken into account, donations
from individuals were not biased towards either gender,
with approximately an equal number of female (45.9 %,
759/1403) and male (54.1 %, 644/1403) donors. Sero-
positivity within males over the four-year period (2006–
2009) was 12.3 % (79/644) (95 % CI: 9.8–15.1 %), com-
pared to 13.7 % (106/759) (95 % CI: 11.6–16.3 %) in
females.
Evidence of seroconversion over a four-year period
(2006–2009) and detection of sporozoite specific
antibodies
Longitudinal analysis of individuals over this four-year
period allowed identification of individuals and monitor-
ing for their T. gondii IgG status over time (seroconver-
sion or reversion). A total of 184 individuals donated
within all four collection periods, using the cut-off value
(logODc = -0.48), clear seroconversion (T. gondii sero-
negative to seropositive) was observed in 1.1 % (2/184)
of individuals and reversion (seropositive to seronega-
tive) in 3.3 % (6/184) of individuals. Not all samples were
available for testing with the TgERP ELISA, however, ten
individuals who had shown seroconversion within at least
two subsequent blood donations were tested (Table 2).
Using a positive cut-off value for the TgERP ELISA of
OD 0.41, the presence of sporozoite specific antigen was
identified from only one sample (donor C collection
Table 1 Toxoplasma gondii seropositivity by collection period. Seroprevalence takes into account repeat donations from each
collection period. *repeat donations taken across all collection periods where each individual is counted only once over the four-
year period (2006-2009)
Period Collection period No. of samples (includes
repeat donations) (n)
No. of individuals (no
repeat donations) (n)
No. of T. gondii positive








947 947 113 11.9 9.9–14.2
2 July 2006–
August 2007
811 811 105 12.9 10.7–15.5
3 April 2008–
September 2008
766 697 84 12.1 9.7–14.7
4 September 2008–
February 2009
749 606 76 12.5 10.0–15.4
*1–4 April 2006–
February 2009





























Fig. 2 T. gondii seropositivity by ELISA of Scottish blood donors in relation to age (2006–2009). Error bars indicate 95 % confidence intervals
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period 3, Table 2). However, two subsequent samples
from this donor were TgERP negative (collection period
4, Table 2). The remaining nine donors were TgERP
negative (TgERP ELISA OD < 0.41).
Prevalence of T. gondii DNA in human brain tissue
collected over a five-year period
Molecular detection of parasite DNA by ITS1 PCR from
all samples (irrespective of age, gender or cause of death)
over a five-year period (2008–2012 inclusive), has shown
an overall detection rate of 17.9 % (27/151) (95 % CI:
12.1–24.0 %) (Table 3). The number of positive samples
varied throughout the five-year period, with T. gondii
DNA detected in 22.9 % (8/35) (95 % CI: 10.4–40.1 %)
of individuals in 2008, 5.4 % (2/37) (95 % CI: 0.7–
18.2 %) in 2009 and 15.8 % (6/38) (95 % CI: 6.0–31.3 %)
in 2010. There were a greater number of positive sam-
ples in 2011 to 26.1 % (6/23) (95 % CI: 10.8–48.4 %) and
in 2012 27.8 % (5/18) (95 % CI: 10.2 %–48.4 %) of sam-
ples were positive.
Table 2 Evidence of T. gondii IgG seroconversion or reversion and TgERP antibody response in Scottish blood donors (2006–2009)
Donor Positive logODc Collection period Date Status TgERP ELISA Result (OD)
A N −0.50 1 May 2006 0.20
A Y −0.27 2 April 2007 SEROCONVERTED 0.29
A Y −0.28 3 July 2008 0.19
B N −0.87 1 May 2006 0.20
B N −0.81 2 August 2006 0.21
B N −1.01 4 September 2008 0.21
B Y −0.02 4 January 2009 SEROCONVERTED 0.22
C N −0.89 1 April 2006 0.39
C Y 0.25 3 May 2008 SEROCONVERTED 1.38#
C Y 0.13 4 September 2008 0.38
C Y 0.03 4 December 2008 0.27
D N −0.63 1 May 2006 0.22
D N −0.77 2 November 2006 0.17
D N −0.99 3 August 2008 0.12
D Y 0.00 4 December 2008 SEROCONVERTED 0.15
E N −0.51 1 May 2006 0.17
E Y 0.12 2 January 2007 SEROCONVERTED 0.16
F N −0.58 1 June 2006 0.18
F N −0.52 2 September 2006 0.22
F Y −0.43 3 April 2008 SEROCONVERTED 0.20
F N −0.55 3 July 2008 REVERSION 0.23
F Y −0.22 4 November 2008 SEROCONVERTED 0.32
G N −0.80 1 June 2006 0.15
G N −0.74 2 October 2006 0.24
G N −0.74 3 June 2008 0.28
G Y −0.37 4 November 2008 SEROCONVERTED 0.23
G N −0.93 4 February 2009 REVERSION 0.25
H N −0.66 1 July 2006 0.25
H Y −0.29 4 February 2009 SEROCONVERTED 0.25
I N −0.79 3 July 2008 0.14
I Y −0.36 4 December 2008 SEROCONVERTED 0.14
J N −0.79 3 August 2008 0.23
J Y −0.08 4 December 2008 SEROCONVERTED 0.14
Cut-off values: a) logODc cut-off value for T. gondii IgG ELISA = −0.48 b) OD cut-off value for TgERP analysis = 0.41. Key: Y = positive IgG result (and also
highlighted in bold), N = negative IgG result, # = positive in TgERP ELISA
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Effect of age and gender on parasite DNA detection in
human brains
Overall, a greater number of samples were obtained
from males, which consisted of 79.5 % (120/151) of all
individuals. This gender bias towards males was evident
across all ages (data not shown). The greatest number of
brain samples was obtained from the 56–69 age group,
which accounted for 31.8 % (48/151; males n = 40,
females n = 8) of all samples.
Using combined results, for the five-year period, the
prevalence of T. gondii detected in human brains in-
creased between the ages of 17–69 (Fig. 3), however, de-
tection levels dropped within the 70–80 age group and
the 81–91 age group, however this may be due to a reduced
sample size for these two age groups (n = 20 and n = 5,
respectively) compared to the other age groups (17–29,
n = 11; 30–42, n = 21; 43–55, n = 46; 56–69, n = 48).
Relationship between cause of death and parasite
detection
Anonymised information from the MRC Sudden Death
Brain and Tissue Bank also provided details about the
cause of death. The predominant cause of death for all
individuals from whom samples were obtained was due to
heart disease/heart attack, which accounted for 64.9 %
(98/151) (95 % CI: 56.7–72.5 %) of all cases. The second
most common cause of death was due to suicide (6.0 %, 9/
151) (95 % CI: 1.5–8.4 %), followed by those who died due
to drug overdose (5.3 %, 8/151) (95 % CI: 2.3–10.2 %).
Further analysis of cause of death and the detection of
T. gondii DNA from the brain of each individual has
highlighted that 18.4 % (18/98) (95 % CI: 11.3–27.5 %)
of people who died of a heart attack were positive for T.
gondii, which is not significantly different from positivity
in people who died of other causes (9/53, 17.0 %, 95 %
CI: 8.1–29.8 %, Fisher’s exact test P = 1.00). There were
significantly fewer samples available from other cases of
sudden death (Additional file 1: Table S1), therefore no
comparisons between cause of death and detection of
parasite DNA could be made.
Strain genotyping using SAG3 and GRA6
Although multiple attempts were made to amplify DNA
from all individuals who were identified as positive for
T. gondii by ITS1 PCR (n = 27), only three samples could
be genotyped by PCR-RFLP at the SAG3 locus and one
sample at the GRA6 locus (Table 4). The results identified
two type III and two type I alleles from four different indi-
viduals. T. gondii DNA from one individual (A/08) could
be sequenced at the GRA6 locus (Fig. 4), and the SAG3
Table 3 Molecular detection of T. gondii DNA from human brains by year (2008–2012)
Year No. of samples (n) T. gondii positive (%) 95 % CI (lower and upper values)
2008 35 22.9 (n = 8) 10.4–40.1
2009 37 5.4 (n = 2) 0.6–18.2
2010 38 15.8 (n = 6) 6.0–31.3
2011 23 26.1 (n = 6) 10.2–48.4
2012 18 27.8 (n = 5) 9.7–53.5






























Fig. 3 Detection of T. gondii DNA by ITS1 PCR in brains of humans in relation to age (2008–2012). Error bars indicate 95 % confidence intervals
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locus from another individual (D/11) (Fig. 5), this
confirmed the identification of T. gondii type I and
type III alleles within the human brain tissues.
Discussion
The primary aim of this study was to obtain an estimate
of T. gondii infection in the Scottish population using
two different study groups. First, we used samples from
Scottish blood donors who represent a broad age range
of individuals and also includes a similar number of
samples from both males and females, (as opposed to
the majority of T. gondii seroprevalence studies which
mainly focus on women of childbearing age). Secondly,
prevalence was also determined by molecular detection
of parasite DNA from brain tissues of individuals who
had died suddenly, with no known underlying clinical
disease.
When examining the seroprevalence of T. gondii from
Scottish blood donors over a four-year period (2006–
2009), the result was estimated to be 13.2 % (95 % CI:
11.5–15.1 %) (Table 1). This figure is lower but not sub-
stantially different from the prevalence determined by
molecular detection in human brains over a five-year
period (2008–2013), which was estimated at 17.9 %
(95 % CI: 12.1–24.9 %) (Table 3), and is likely influenced
by differences in study population (e.g. age distribution)
and detection method. Within both study groups there
appears to be a direct link between increasing positivity
and increasing age (Figs. 2 and 3). Therefore, samples
that have originated from older individuals is the likely
reason behind the higher prevalence figure observed
within human brain samples. This correlation between
age and prevalence of the parasite has been described in
humans and animals [21–24]. The molecular detection
of the parasite from human brains initially follows this
pattern (Fig. 3), however prevalence begins to fall from
the 70–80 age group. The observed reduction in preva-
lence may be due to the reduced sample size (n = 20);
however, without a greater sample size from this age
group, it is not possible to say whether this trend would
have continued.
Using blood donors allowed repeat donors to be
followed longitudinally. Once the serology data was
analysed using the cut-off value (log ODc = -0.48), as
Table 4 T. gondii PCR-RFLP genotyping across two markers from four infected humans
PCR-RFLP genotyping
Sample ID Gender Age Cause of death SAG3 GRA6 Alleles identified
A/08 M 58 Heart attack/disease na Ib I
B/10 M 50 Heart attack/disease III na III
C/10 M 27 Drug overdose Ia na I
D/11 M 58 Heart attack/disease IIIb na III
aweak band; bsequencing completed; na, no amplification
I = type I; III = type III; M =Male
Fig. 4 GRA6 sequence of T. gondii detected from a human brain. Consensus sequence indicates the nucleotides shared by a minimum of two of
the three archetypal clonal lineages RH (type I), Me49 (II), and CEP (III), GenBank accession numbers AF239283, AF239285 and AF239287, respectively.
Sequencing shows that T. gondii type I was identified from a human brain (sample ID 19-08), using GRA6 primers
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calculated using the binomial mixture model (Fig. 1), it
was possible to identify individuals who, over time, had
become seropositive or had reverted back to seronega-
tive status. When examining individuals who had do-
nated within all four collection periods (n = 184)
seroreversion was greater than seroconversion (3.3 % (6/
184) and 1.1 % (2/184) respectively), which is an occur-
rence rarely reported within the current literature.
TgERP ELISA was performed on available samples that
had shown seroconversion over at least two subsequent
donations (n = 10). One positive serum sample (Table 2,
donor C) was identified, indicating that this individual
had been infected by ingestion of sporulated oocysts
other than infection with bradyzoites (tissue cysts). It
was also observed that following the positive result from
the T. gondii IgG ELISA, the log ODc value for this sam-
ple (collection period May 2008), was greater than any
other sample tested (log ODc = 0.25) as shown in Table 2.
Antibodies to the sporozoite antigen could not be de-
tected in the remaining samples which could indicate
that these individuals were infected with tissue cysts.
Another reason for a negative result could be because
the level of TgERP antibody has dropped below a detect-
able level, as these antibodies are described to persist for
6–8 months [12], or that individuals were infected with
such a low number of oocysts that although an IgG re-
sponse against the tachyzoite stage was established, this
contained too few sporozoites to generate an antibody
response to the TgERP protein. In comparison to the
sample which gave a positive result for the sporozoite
antigen, the log ODc values following the T. gondii IgG
ELISA using tachyzoite antigen were lower for these in-
dividuals which may have affected the sensitivity of the
TgERP assay.
In conjunction with the collection of human brain tis-
sues from the Sudden Death Brain Bank, the cause of
death for each individual was recorded (in addition to
age and gender). Cause of death included those who had
committed suicide, had been involved in fatal road traffic
accidents, but also included a broad range of other fac-
tors which can cause sudden death (e.g. heart attack,
brain haemorrhage and stroke). The results showed no
clear association between cause of death and molecular
detection of T. gondii. One of the most frequent causes
of death for the UK population is heart attack, second
only to cancer [25] and the majority of brain samples
came from cases of sudden death due to heart attack/
disease [64.9 % (98/151) (95 % CI: 56.7–72.5 %)]. In
addition, the percentage positivity of individuals who
died of a heart attack, who also had T. gondii DNA de-
tected in their brain, was 18.4 % (18/98) (95 % CI: 11.3–
27.5 %), this figure is not significantly different from the
overall prevalence of 17.0 % (9/53) (95 % CI: 8.1–29.8 %)
in those that died of other causes of sudden death.
Therefore, it is unlikely that the prevalence of T. gondii
has any role or association with heart attack/disease.
Nevertheless, several publications have reported the po-
tential involvement with T. gondii and complications
with the heart [26–28], and more recently a publication
described a possible link to acute myocardial infarction
(AMI) and T. gondii infection [29], where 66.7 % (32/48)
of cases of AMI were also associated with the presence
of anti-T. gondii IgG. However, any possible link between
the parasite and heart complications will require further
investigation, and would need to take into account age,
diet and lifestyle habits.
Results from both the serological and molecular detec-
tion of the parasite provide more contemporary informa-
tion on the prevalence of the parasite within the Scottish
population. The results from the serology study show
that there is very little variation between seroprevalence
and each collection period (2006–2009), which varied
from 11.9 % (113/947) (95 % CI: 9.9–14.2 %) in collec-
tion period 1 to a maximum of 12.9 % (105/811) (95 %
CI: 10.7–15.5 %) in collection period 2 (Table 1). In con-
trast, the prevalence determined by molecular detection
of the parasite varied from year to year, with 5.4 % (2/37)
(95 % CI: 0.6–18.2 %) being the lowest level recorded in
Fig. 5 SAG3 sequence of T. gondii detected from a human brain. Consensus sequence indicates the nucleotides shared by a minimum of two of
the three archetypal clonal lineages RH (type I), Pru (II), and CEP (III), GenBank accession numbers AF340227, AF340228 and AF340229,
respectively. Sequencing shows that T. gondii type III was identified from a human brain (sample ID 13-11), using SAG3 primers
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2009 and 27.8 % (5/18) (95 % CI: 12.1–24.9 %) in 2012
(Table 3). The year by year variation observed by molecu-
lar detection is likely to be due to both the inhomogen-
eous distribution of tissue cysts in the brain and, in the
case of year 2012, too small a sample size (n = 18) to be
considered representative of that year.
When comparing these figures to previous studies, a
serological study from blood donors in Scotland (from
both rural and urban areas) gave an average seroprevalence
of 7.7 % (n = 182) [10], however these results were pub-
lished in 1987. Three years after these published results, a
seroprevalence study from blood donors throughout the
British Isles between 1990 and 1991 was conducted, which
highlighted a prevalence of between 11–40 % depending
on the region (as described in [2]). When using this data
and taking the average figure for Scotland only, sero-
prevalence is calculated at 15 %, which is similar to the
seroprevalence in the current study (13.2 %) (95 % CI:
11.5–15.1 %). More recently (2012), a study looking
specifically at pregnant women, which included 2610
women in London, reported a seroprevalence of 17.3 %
[7]. This result is similar to our reported figure for the
molecular detection of the parasite (17.9 %, 95 % CI:
12.1–24.9 %). However, in this publication, when the
figure was adjusted to include only those of UK origin
(67.7 %), the figure dropped to 11.9 %, again, this is
similar to the overall seroprevalnce in our current study
(Table 1). However, the results reported within this
body of work are not only from sera and tissue col-
lected recently, but are from both genders, across a
broad age range (17–91 years), and are therefore more
representative of the current population than studies
carried out on pregnant women or blood donors from
up to nearly three decades ago. The prevalence of T.
gondii in Scotland appears to be low when compared to
other European countries, such as Germany and
France, where prevalence has been reported to be as
high as 59.0 % (n = 4854) and 54.0 % (n = 13,459) re-
spectively [30, 31]. The variation between countries is
likely to be due to different consumption habits of raw
or undercooked meat within these countries [32]. Al-
though a low seroprevalence rate for T. gondii within a
population is good (as cases of ocular toxoplasmosis
due to acquired infection are less likely), it also high-
lights a potential risk for women to become infected
(for the first time) during pregnancy.
Although strain genotyping by PCR-RFLP was not par-
ticularly successful (most likely due to genotyping based
on single copy markers in combination with a high con-
centration of host DNA compared to a low concentra-
tion of parasite DNA), two different alleles (type I and
type III) from four individuals were identified (Table 4).
In addition, direct sequencing of two of these amplified
PCR products, using GRA6 and SAG3 markers, further
confirmed the results observed by PCR-RFLP (Figs. 4
and 5). Type II is known to be the most common geno-
type circulating within Europe [33] however alleles for
type I and III have also been identified from carnivorous
wildlife in the UK [20]. Due to the invasive process re-
quired for obtaining human tissue samples, information
on parasite genotypes found in humans is limited, but it
is known that specific strains (in particular atypical
strains) are more likely to cause a difference in the se-
verity of disease and hence the clinical symptoms ob-
served [34–37], similar to what has also been reported
in animal species [38, 39].
Conclusions
Overall this research provides up-to-date information
about the prevalence of the parasite in humans, data
which has been reported as lacking in a recent report by
the Advisory Committee on the Microbiological Safety
of Food [2] and also provides a novel insight into the ge-
notypes which may be present within the UK popula-
tion. The longitudinal study allowed sera from individual
blood donors to be tracked over time and has shown not
only evidence of seroconversion, but also seroreversion
which is rarely reported within the literature.
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